Predictive Values of Serotonergic Alterations for Outcome - 2

This study has been terminated.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Department of Veterans Affairs
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000313

Purpose

The purpose of this study is to evaluate the predictive value of serotonergic alterations for outcome.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Fenfluramine	Phase I

Drug Information available for: Fenfluramine Fenfluramine hydrochloride

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Predictive Values of Serotonergic Alterations for Outcome

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:

Eligibility

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000313

Locations

United States, New York
VA Medical Center
Brooklyn, New York, United States, 11209

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Department of Veterans Affairs

Investigators

Principal Investigator:

Laure Buydens-Branchey, M.D.

Department of Veterans Affairs

More Information

Study ID Numbers:	NIDA-09468-2, R01-09468-2
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000313
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Mental Disorders
Substance-Related Disorders

Disorders of Environmental Origin
Fenfluramine
Serotonin

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Serotonin Agents
Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs
Serotonin Uptake Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009